M&As Most Active For Small China Biopharma Firms As Regulation Costs Bite
This article was originally published in PharmAsia News
Executive Summary
Mergers & acquisitions among small- and medium-sized biopharma companies in China have witnessed strong momentum in the past year, with 31 completed since July 2012 and 61 in progress, according to a report.